Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Hormone Replacement Therapy
Pharma
After 2 delays, FDA approves Ascendis' Yorvipath
After two delays, the FDA has signed off on Ascendis' Yorvipath, which is the first approved product for hypoparathyroidism in adults in the U.S.
Kevin Dunleavy
Aug 12, 2024 11:10am
Ascendis must wait 3 more months for FDA verdict on TransCon PTH
May 14, 2024 5:36pm
Ascendis' hormone drug gets manufacturing-related CRL
May 1, 2023 2:32pm
Folx Health plans for the LGBTQ+ future by honoring its past
Jul 8, 2022 9:00am
Grants help transgender community be who they are
Apr 8, 2022 7:50am
Alloy turns up heat on men to shed light on menopause symptoms
Feb 17, 2022 9:20am
